Carcinoma of the urinary bladder

S. M. Cohen, G. H. Friedell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) reproducibly induces a 100% incidence of tumors of the urinary bladder in rats, mice, hamsters, and dogs without sex predominance. Only bladder tumors occur when FANFT is fed at a dose of 0.2% of the diet to weanling male inbred Fischer 344 rats; if FANFT is administered for the lifetime of the rats or for 25 or 36 weeks followed by control diet, all of the rats die from bladder cancer before the age of 20 months. FANFT-induced bladder carcinomas resemble the human disease in several ways. Most of the lesions are of transitional cell type and papillary, although most advanced tumors are polypoid masses protruding into the lumen (a rather uncommon form of human bladder cancer). As with the human disease, the FANFT-induced lesions progress from epithelial hyperplasia to noninvasive carcinoma, invasion, and eventually distant metastases. The progression of the disease in the rat can be followed by urinary cytology, and hematuria is a frequent early sign of the disease, as it is in the human. The use of an inbred strain makes possible studies on tumor-host interaction, including various immunologic studies, during different stages of the disease. The model is also useful for studies of other aspects of bladder cancer, including biochemical changes in the host during carcinogenesis, and various therapeutic investigations. A two-stage process in bladder carcinogenesis has recently been demonstrated using FANFT as an initiating agent, and the model may be a useful way to investigate possible promoting agents and possible initiating agents.

Original languageEnglish (US)
Pages (from-to)849-852
Number of pages4
JournalAmerican Journal of Pathology
Volume95
Issue number3
StatePublished - Dec 1 1979

Fingerprint

FANFT
Urinary Bladder
Carcinoma
Urinary Bladder Neoplasms
Carcinogenesis
Diet
Neoplasms
Inbred F344 Rats
Hematuria
Cricetinae
Hyperplasia
Cell Biology
Disease Progression
Dogs
Neoplasm Metastasis
Incidence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Carcinoma of the urinary bladder. / Cohen, S. M.; Friedell, G. H.

In: American Journal of Pathology, Vol. 95, No. 3, 01.12.1979, p. 849-852.

Research output: Contribution to journalArticle

Cohen, SM & Friedell, GH 1979, 'Carcinoma of the urinary bladder', American Journal of Pathology, vol. 95, no. 3, pp. 849-852.
Cohen, S. M. ; Friedell, G. H. / Carcinoma of the urinary bladder. In: American Journal of Pathology. 1979 ; Vol. 95, No. 3. pp. 849-852.
@article{1c205db9a83a4ccdaece4e43892791a7,
title = "Carcinoma of the urinary bladder",
abstract = "N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) reproducibly induces a 100{\%} incidence of tumors of the urinary bladder in rats, mice, hamsters, and dogs without sex predominance. Only bladder tumors occur when FANFT is fed at a dose of 0.2{\%} of the diet to weanling male inbred Fischer 344 rats; if FANFT is administered for the lifetime of the rats or for 25 or 36 weeks followed by control diet, all of the rats die from bladder cancer before the age of 20 months. FANFT-induced bladder carcinomas resemble the human disease in several ways. Most of the lesions are of transitional cell type and papillary, although most advanced tumors are polypoid masses protruding into the lumen (a rather uncommon form of human bladder cancer). As with the human disease, the FANFT-induced lesions progress from epithelial hyperplasia to noninvasive carcinoma, invasion, and eventually distant metastases. The progression of the disease in the rat can be followed by urinary cytology, and hematuria is a frequent early sign of the disease, as it is in the human. The use of an inbred strain makes possible studies on tumor-host interaction, including various immunologic studies, during different stages of the disease. The model is also useful for studies of other aspects of bladder cancer, including biochemical changes in the host during carcinogenesis, and various therapeutic investigations. A two-stage process in bladder carcinogenesis has recently been demonstrated using FANFT as an initiating agent, and the model may be a useful way to investigate possible promoting agents and possible initiating agents.",
author = "Cohen, {S. M.} and Friedell, {G. H.}",
year = "1979",
month = "12",
day = "1",
language = "English (US)",
volume = "95",
pages = "849--852",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Carcinoma of the urinary bladder

AU - Cohen, S. M.

AU - Friedell, G. H.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) reproducibly induces a 100% incidence of tumors of the urinary bladder in rats, mice, hamsters, and dogs without sex predominance. Only bladder tumors occur when FANFT is fed at a dose of 0.2% of the diet to weanling male inbred Fischer 344 rats; if FANFT is administered for the lifetime of the rats or for 25 or 36 weeks followed by control diet, all of the rats die from bladder cancer before the age of 20 months. FANFT-induced bladder carcinomas resemble the human disease in several ways. Most of the lesions are of transitional cell type and papillary, although most advanced tumors are polypoid masses protruding into the lumen (a rather uncommon form of human bladder cancer). As with the human disease, the FANFT-induced lesions progress from epithelial hyperplasia to noninvasive carcinoma, invasion, and eventually distant metastases. The progression of the disease in the rat can be followed by urinary cytology, and hematuria is a frequent early sign of the disease, as it is in the human. The use of an inbred strain makes possible studies on tumor-host interaction, including various immunologic studies, during different stages of the disease. The model is also useful for studies of other aspects of bladder cancer, including biochemical changes in the host during carcinogenesis, and various therapeutic investigations. A two-stage process in bladder carcinogenesis has recently been demonstrated using FANFT as an initiating agent, and the model may be a useful way to investigate possible promoting agents and possible initiating agents.

AB - N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) reproducibly induces a 100% incidence of tumors of the urinary bladder in rats, mice, hamsters, and dogs without sex predominance. Only bladder tumors occur when FANFT is fed at a dose of 0.2% of the diet to weanling male inbred Fischer 344 rats; if FANFT is administered for the lifetime of the rats or for 25 or 36 weeks followed by control diet, all of the rats die from bladder cancer before the age of 20 months. FANFT-induced bladder carcinomas resemble the human disease in several ways. Most of the lesions are of transitional cell type and papillary, although most advanced tumors are polypoid masses protruding into the lumen (a rather uncommon form of human bladder cancer). As with the human disease, the FANFT-induced lesions progress from epithelial hyperplasia to noninvasive carcinoma, invasion, and eventually distant metastases. The progression of the disease in the rat can be followed by urinary cytology, and hematuria is a frequent early sign of the disease, as it is in the human. The use of an inbred strain makes possible studies on tumor-host interaction, including various immunologic studies, during different stages of the disease. The model is also useful for studies of other aspects of bladder cancer, including biochemical changes in the host during carcinogenesis, and various therapeutic investigations. A two-stage process in bladder carcinogenesis has recently been demonstrated using FANFT as an initiating agent, and the model may be a useful way to investigate possible promoting agents and possible initiating agents.

UR - http://www.scopus.com/inward/record.url?scp=0018742601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018742601&partnerID=8YFLogxK

M3 - Article

C2 - 453337

AN - SCOPUS:0018742601

VL - 95

SP - 849

EP - 852

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -